News
FBRX
20.58
-7.51%
-1.67
Weekly Report: what happened at FBRX last week (0629-0703)?
Weekly Report · 2d ago
Weekly Report: what happened at FBRX last week (0622-0626)?
Weekly Report · 06/29 10:26
Weekly Report: what happened at FBRX last week (0615-0619)?
Weekly Report · 06/22 10:37
Weekly Report: what happened at FBRX last week (0608-0612)?
Weekly Report · 06/15 10:37
Weekly Report: what happened at FBRX last week (0601-0605)?
Weekly Report · 06/08 10:32
At a glance: stocks gapping up premarket
Seeking Alpha · 06/03 10:58
Forte Biosciences Shareholders Approve Directors and Governance Items
TipRanks · 06/02 21:52
Forte Biosciences Files $500M Shelf Registration For Potential Issuance Of Common Stock, Preferred Stock, Debt Securities, Warrants, And Other Securities From Time To Time
Benzinga · 06/02 20:49
FORTE BIOSCIENCES - MAY OFFER UP TO $500 MLN IN SECURITIES - SEC FILING
Reuters · 06/02 20:40
Forte Biosciences shareholders approve amended, restated 2021 equity incentive plan at annual meeting
PUBT · 06/02 20:02
Weekly Report: what happened at FBRX last week (0525-0529)?
Weekly Report · 06/01 10:38
Weekly Report: what happened at FBRX last week (0518-0522)?
Weekly Report · 05/25 10:42
Weekly Report: what happened at FBRX last week (0511-0515)?
Weekly Report · 05/18 10:41
Forte Biosciences: Targeting Celiac Disease
Seeking Alpha · 05/16 05:55
Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Metagenomi, Inc. (MGX)
TipRanks · 05/11 21:50
Forte Biosciences: Buy Rating Backed by FB102 Pipeline Momentum and Multiple Upcoming Clinical Catalysts
TipRanks · 05/11 20:25
Forte Biosciences grants new hire options, RSUs covering 100,000 shares
PUBT · 05/11 20:01
FORTE BIOSCIENCES, INC. REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULES
Reuters · 05/11 20:01
Forte Biosciences reports Q1 EPS ($1.24), consensus ($1.16)
TipRanks · 05/11 14:15
Forte Biosciences Q1 net loss narrows as R&D spending rises
Reuters · 05/11 13:10
More
Webull provides a variety of real-time FBRX stock news. You can receive the latest news about Forte Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBRX
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.